Teleflex (NYSE:TFX) said its ultrasound device, the Arrow VPS G4, will be available in the U.S. in the 2nd quarter this year.
The FDA cleared the device for use in conjunction with Teleflex’s disposable Arrow VPS Stylet.
The new Arrow device uses micro-doppler ultrasound and intravascular electrocardiography to locate a specific location of the vena cava and cavo-atrial junction. Finding this small location in the heart is important when placing a peripherally inserted central catheter.
"There are more than 3 million PICCs and 2 million CVCs placed in the United States each year," said Paul Molloy, president of Teleflex’s vascular division, in prepared remarks. "The Arrow VPS G4 device is a reliable and easy-to-use system designed to help reduce complications and reduce patient exposure to radiation."
The Limerick, Pa.-based device company also recently won FDA clearance for its latest line of peripheral nerve block needles, the Arrow UltraQuik.
